{
  "meta": {
    "timestamp": "2025-01-06T14:20:55.193698",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Enliven Therapeutics Inc.",
      "symbol": "ELVN",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory and clinical trial risks due to dependence on FDA approval for drug candidates",
            "Heavy reliance on external funding, making the company vulnerable to market fluctuations",
            "Highly competitive oncology space with uncertain market penetration",
            "Insider selling by CFO, potentially indicating lack of confidence in near-term prospects"
          ],
          "controversies": [
            "Insider selling by CFO Benjamin Hohl in December 2023"
          ],
          "environmental_issues": [],
          "social_issues": [
            "High cost of targeted therapies may raise concerns about accessibility and affordability"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Enliven Therapeutics Closes Merger with Imara and Private Placement of ...",
              "snippet": "The combined company will operate under the name, Enliven Therapeutics, Inc., and its shares will trade on the Nasdaq Global Select Market on February 24, 2023 under the ticker symbol \"ELVN\". ... the ability to obtain regulatory approval for, and ultimately commercialize, product candidates; the outcome of preclinical testing and early ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904651+00:00",
              "published_date": null,
              "source_hash": "2d5a69f62081474c591b0858732043e5"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Reports First Quarter Financial Results and ...",
              "snippet": "BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2024, and provided a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904758+00:00",
              "published_date": null,
              "source_hash": "ceb2878a2b598fd0512767ed0c0ff122"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Announces Positive Proof of Concept Data from ...",
              "snippet": "Enliven Therapeutics, Inc. Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790823+00:00",
              "published_date": null,
              "source_hash": "9b65593a78dedd7d47da32112ad2b84b"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics, Inc. (ELVN) - Stock Analysis",
              "snippet": "Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. ... Imara Announces Stockholder Approval of Merger With Enliven-- Combined Company to Trade on Nasdaq Under Ticker \"ELVN\" -- -- Imara Announces 1-for-4 Reverse Stock ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904782+00:00",
              "published_date": null,
              "source_hash": "bddccb2865547a6d6bc1cad642142677"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Announces Positive Proof of Concept Data from ...",
              "snippet": "BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790784+00:00",
              "published_date": null,
              "source_hash": "44c6df18129db209eefb2dd85e028c9d"
            },
            {
              "url": "",
              "title": " Company Presentation - Enliven Therapeutics",
              "snippet": "4 Merger of Enliven and Imara \u2022 Merger with Enliven, a privately held precision oncology company \u2022 Strong balance sheet of approximately $300 million of cash and cash equivalents expected to provide funding for operations into early 2026 \u2022 Upon close, company expected to be renamed \"Enliven Therapeutics, Inc.\" trading as Nasdaq: ELVN \u2022 Supported by the Board of Directors of both ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.937931+00:00",
              "published_date": null,
              "source_hash": "dba44f3ac13054be25d3491232927f29"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Reports Second Quarter Financial Results and ...",
              "snippet": "Enliven Therapeutics, Inc. Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904817+00:00",
              "published_date": null,
              "source_hash": "26e95310b45d82dd49499d32539c5ad2"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Announces $90 Million Private Placement Financing ...",
              "snippet": "Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904825+00:00",
              "published_date": null,
              "source_hash": "691992ea164ca07d5ca42e9761045a01"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics, Inc. - ELVN - Stock Price Today - Zacks",
              "snippet": "Get the latest Enliven Therapeutics, Inc ELVN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... There may be delays, omissions, or inaccuracies in the Information. 3/13 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904835+00:00",
              "published_date": null,
              "source_hash": "20726ca1d5bf64386abc2049a0f0dceb"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Reports Third Quarter Financial Results and ...",
              "snippet": "Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:27.904843+00:00",
              "published_date": null,
              "source_hash": "921ac07e55b3a654da55263be00374b8"
            },
            {
              "url": "",
              "title": "Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet",
              "snippet": "Enliven Therapeutics, Inc. (ELVN) closed the last trading session at $23.77, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:30.408989+00:00",
              "published_date": "2024-08-17T02:28:00+00:00",
              "source_hash": "d5a45dc6b2d015cd4ebe3a8451951efe"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 900 Shares of Stock",
              "snippet": "CFO Benjamin Hohl sold 900 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $22.51, for a total value of $20,259.00. The transaction was disclosed in a filing with the SEC,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:41.904889+00:00",
              "published_date": "2025-01-01T09:58:00+00:00",
              "source_hash": "b3664601856222d242f0ac4c02ab63ce"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Inc (ELVN)",
              "snippet": "After-Hours Stock Movers: Imara Inc (NASDAQ:IMRA) 19% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of... Investing.com ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:20:30.409081+00:00",
              "published_date": "2025-01-02T20:59:00+00:00",
              "source_hash": "b2af1f5aa8777a243396e9192582762b"
            },
            {
              "url": "",
              "title": "Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going",
              "snippet": "Enliven Therapeutics, Inc. (ELVN) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for \"trend\" investors.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:41.905006+00:00",
              "published_date": "2024-09-26T16:46:00+00:00",
              "source_hash": "dc13357864d5d16839ca26b687b5097f"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics (NASDAQ:ELVN) Shares Down 2.9% - Here's Why",
              "snippet": "Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) fell 2.9% on Tuesday . The company traded as low as $22.53 and last traded at $22.74. 10,609 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 253,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:41.904971+00:00",
              "published_date": "2024-12-26T09:29:00+00:00",
              "source_hash": "4bb2f4eb251616d4cb290d58d2dd8927"
            },
            {
              "url": "",
              "title": " Merger Announcement - Enliven Therapeutics",
              "snippet": "4 Merger of Enliven and Imara \u2022 Merger with Enliven, a privately held precision oncology company \u2022 Strong balance sheet of approximately $300 million of cash and cash equivalents expected to provide funding for operations into early 2026 \u2022 Upon close, company expected to be renamed \"Enliven Therapeutics, Inc.\" trading as Nasdaq: ELVN \u2022 Supported by the Board of Directors of both ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938039+00:00",
              "published_date": null,
              "source_hash": "9251a454c3180776481920e30c4a5018"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Provides Corporate Update on Financing, Expansion ...",
              "snippet": "Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938054+00:00",
              "published_date": null,
              "source_hash": "43f24af4a5afe039e6302d7d90e2980f"
            },
            {
              "url": "",
              "title": "Enliven Therapeucs, Inc.",
              "snippet": "\u2022 Net Loss: Enliven reported a net loss of $14.7 million for the \ufb01rst quarter of 2023, compared to a net loss of $8.7 million for the \ufb01rst quarter of 2022. About Enliven Therapeucs. Enliven Therapeucs is a clinical-stage biopharmaceucal company focused on the discovery and development of small molecule inhibitors to help",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938065+00:00",
              "published_date": null,
              "source_hash": "e0c63904d2cbc8bb7e56ebd06c3ae850"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Inc. - MarketWatch",
              "snippet": "Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market Dec. 10, 2024 at 1:55 p.m. ET on ... Enliven Therapeutics Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938075+00:00",
              "published_date": null,
              "source_hash": "50dab761b60a2865287cbe3174b9491b"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Company Profile 2025: Stock ... - PitchBook",
              "snippet": "Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938085+00:00",
              "published_date": null,
              "source_hash": "9fffb8ac35bc900504c126d0f62b55a3"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics, Inc. (ELVN) Company Profile & Overview - Stock ...",
              "snippet": "Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790880+00:00",
              "published_date": null,
              "source_hash": "7f1cbd7bc58fad22571acf7fdb4308db"
            },
            {
              "url": "",
              "title": "ELVN | Enliven Therapeutics Inc. Profile | MarketWatch",
              "snippet": "Enliven Therapeutics Inc. Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938107+00:00",
              "published_date": null,
              "source_hash": "b35367214d277ed9d9d04eade4b1146f"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer ...",
              "snippet": "Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst. HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:31.938116+00:00",
              "published_date": null,
              "source_hash": "420845569f9aad3848d530b21459f010"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics | Small Molecule Kinase Inhibitors",
              "snippet": "Precision Therapeutics. We are developing kinase inhibitors that enhance efficacy through better selectivity and combinability, combat resistance, address brain metastases, and improve safety and patient convenience. Our Approach",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790872+00:00",
              "published_date": null,
              "source_hash": "542910165a1b93864d89b5b9c4cca7d9"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics, Inc.",
              "snippet": "Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:41.904985+00:00",
              "published_date": "2023-02-25T17:32:00+00:00",
              "source_hash": "e48ff024476f1a02fc26c6bdbbd5976b"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Inc.",
              "snippet": "The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. funding challenges",
              "retrieved_at": "2025-01-06T21:20:35.436083+00:00",
              "published_date": "2023-02-27T14:34:00+00:00",
              "source_hash": "f349c24552c4c9fa3b08a6772a4d1878"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of ...",
              "snippet": "Thursday, Enliven Therapeutics Inc (NASDAQ:ELVN) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790834+00:00",
              "published_date": null,
              "source_hash": "e5f6010bb91033f9f86cc94b272d3d6b"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Closes Merger with Imara and Private Placement of ...",
              "snippet": "BOULDER, Colo., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the completion of its previously announced merger.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790842+00:00",
              "published_date": null,
              "source_hash": "8994ab165d982d58af771c6f45a11d4e"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Announces Positive Data Update from Phase 1 ...",
              "snippet": "BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790850+00:00",
              "published_date": null,
              "source_hash": "4c25e1aea622232104f23333bd6f6792"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Highlights Business Achievements and - GlobeNewswire",
              "snippet": "Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results May 11, 2023 16:05 ET | Source: Enliven Therapeutics, Inc. Enliven Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790858+00:00",
              "published_date": null,
              "source_hash": "7589e0ac9d4cbe1bcaebfff378587842"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics Reports Second Quarter Financial Results and ...",
              "snippet": "Enliven Therapeutics, Inc. Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790865+00:00",
              "published_date": null,
              "source_hash": "37855bdd1d007a0b1ac3d2402fda2965"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics' ELVN-001 shows promise in Phase I CML trial",
              "snippet": "Enliven Therapeutics has reported the latest positive results from the Phase I clinical trial showing promise of ELVN-001 for treating patients with chronic myeloid leukaemia (CML). The trial enrolled CML patients irrespective of their T315I mutation status, who have not failed, not responded to or cannot receive existing treatments.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:37.790888+00:00",
              "published_date": null,
              "source_hash": "59c839b0d594e1fc31be7f821db8331f"
            },
            {
              "url": "",
              "title": "Enliven Therapeutics (NASDAQ:ELVN) Stock Quotes, Forecast and News Summary",
              "snippet": "Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why Most of us have heard the dictum \"the trend is your friend.\" And this is undeniably the key to success when it comes ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Enliven Therapeutics Inc. Enliven Therapeutics Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:20:41.904995+00:00",
              "published_date": "2023-02-25T06:19:00+00:00",
              "source_hash": "0eddfd4f6e6390820ea9b0271d53c617"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Enliven Therapeutics Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or issues with FDA or other regulatory approvals for ELVN-001 and ELVN-002",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Enliven Therapeutics Inc. funding challenges",
              "rationale": "Explore risks related to the company's dependence on external funding and potential impacts of market fluctuations",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Enliven Therapeutics Inc. clinical trial controversies",
              "rationale": "Examine any ethical concerns or controversies related to the conduct or outcomes of Enliven's clinical trials",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:20:55.193705",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}